Adjuvant Pembrolizumab Improves QoL in Patients with High-Risk Resected Melanoma
Findings from a secondary analysis of the SWOG S1404 study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1533 results
Approximately 1 Million of New Maternal Orphans Due to Cancer in 2020
Cancer deaths were responsible globally for approximately 15% of prevalent maternal orphans in 2020
FDA Approves Cemiplimab-rwlc in Combination with Platinum-Based Chemotherapy for Advanced NSCLC
Evidence for efficacy is based on the results from the Study 16113
EMA Recommends Extension of Therapeutic Indications for Olaparib
New indication concerns a combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with mCRPC in whom chemotherapy is not indicated
Efficacy and Safety of Trastuzumab Deruxtecan in Exploratory Cohorts of Patients with HER2-Low Gastric or Gastroesophageal Junction Adenocarcinoma
Exploratory cohort results from a phase II study in patients who had not received previously anti-HER2 treatment
FDA Grants Accelerated Approval to Mirvetuximab Soravtansine-gynx for FRα-Positive, Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
FDA also approved the VENTANA FOLR1 (FOLR-2.1) RxDx Assay as a companion diagnostic device
ctDNA-Guided Treatment Influence on Survival in Advanced NSCLC
Findings from the largest prospective, international cohort of patients with advanced non-small cell lung cancer who underwent ctDNA-guided treatment with longitudinal follow-up for survival
EMA Recommends Extension of Therapeutic Indications for Durvalumab
New indication concerns the first-line treatment of biliary tract cancer
Geriatric Assessment Intervention Reduces Patient-Reported Symptomatic Toxicities in Older Patients with Advanced Cancer
Findings from the secondary analysis of the GAP70+ study
Duration of Bevacizumab Maintenance of 15 Months Remains the Standard in Front-Line Treatment for Newly Diagnosed Stage IIB-IV Epithelial Ovarian Cancer
Findings from the AGO-OVAR 17 BOOST study
FDA Approves Tremelimumab in Combination with Durvalumab and Platinum-Based Chemotherapy for Metastatic NSCLC
Evidence for efficacy is based on the results from the POSEIDON study
Adding Tremelimumab to Durvalumab and Chemotherapy Provides Survival Benefit for Patients with Metastatic NSCLC
Findings from the POSEIDON study